Nevro Corp. (NVRO) Analysts See $-0.17 EPS

February 13, 2018 - By Ellis Scott

 Nevro Corp. (NVRO) Analysts See $ 0.17 EPS

Analysts expect Nevro Corp. (NYSE:NVRO) to report $-0.17 EPS on February, 22.They anticipate $0.17 EPS change or 50.00 % from last quarter’s $-0.34 EPS. After having $-0.21 EPS previously, Nevro Corp.’s analysts see -19.05 % EPS growth. The stock increased 0.57% or $0.43 during the last trading session, reaching $75.99. About 146,033 shares traded. Nevro Corp. (NYSE:NVRO) has risen 14.69% since February 14, 2017 and is uptrending. It has underperformed by 2.01% the S&P500.

Nevro Corp. (NYSE:NVRO) Ratings Coverage

Among 13 analysts covering Nevro Corp (NYSE:NVRO), 11 have Buy rating, 1 Sell and 1 Hold. Therefore 85% are positive. Nevro Corp had 31 analyst reports since August 13, 2015 according to SRatingsIntel. Canaccord Genuity maintained Nevro Corp. (NYSE:NVRO) rating on Sunday, October 8. Canaccord Genuity has “Buy” rating and $120.0 target. The stock has “Outperform” rating by Leerink Swann on Tuesday, November 7. BMO Capital Markets maintained Nevro Corp. (NYSE:NVRO) on Thursday, August 31 with “Buy” rating. The stock of Nevro Corp. (NYSE:NVRO) has “Market Outperform” rating given on Tuesday, August 9 by JMP Securities. BMO Capital Markets maintained Nevro Corp. (NYSE:NVRO) rating on Tuesday, July 11. BMO Capital Markets has “Buy” rating and $10600 target. The rating was initiated by Piperjaffray with “Overweight” on Friday, July 22. The firm has “Sell” rating by ValuEngine given on Thursday, May 25. The company was maintained on Sunday, August 6 by Canaccord Genuity. The stock of Nevro Corp. (NYSE:NVRO) earned “Buy” rating by Northland Capital on Thursday, July 6. B. Riley & Co downgraded the shares of NVRO in report on Tuesday, May 9 to “Neutral” rating.

Nevro Corp., a medical device company, focuses on providing products for the patients suffering from chronic pain in the United States and internationally. The company has market cap of $2.25 billion. It develops and commercializes the Senza spinal cord stimulation system, an evidence neuromodulation platform for the treatment of chronic pain. It currently has negative earnings. The firm sells its products through its direct sales force, and a network of sales agents and independent distributors.

More news for Nevro Corp. (NYSE:NVRO) were recently published by:, which released: “Nevro to Report Operating Results for the Fourth Quarter and Full Year 2017” on February 08, 2018.‘s article titled: “Tirschwell & Loewy Inc Buys United Parcel Service Inc, Nevro Corp, Zynga Inc …” and published on February 06, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: